R1 is selected from hydrogen, cyano, C1-3alogenoalkinyl, SO2NRbRc, C0-2alkyl(O)NRbRc, C1-4alkylNBbRc, SO2Ri, C(O)ORa, CH(OH)Rj and C(O)Rj; R2 and R4 are independently selected from hydrogen, halogeno, cyano, NO2, C1-4alkyl, C1-3ahalogenoalkyl, ORa, C(O)NRbRc, SO2Ri, and C(O)ORa; or R1 and R2 together with atoms, to which they are bound, are bound with formation of 5- or 6-member heterocyclic ring, which contains one S, any of the hydrogen atoms of group CH2 in said heterocyclic ring can be substituted by oxo, hydroxy, and sulphur atom in said heterocyclic ring is probably oxydised to -SO2-; R3 and R5 represent hydrogen; R6 represents tetrahydropyran; R7 is selected from hydrogen, C1-3alkyl, cyano and C1-3halogenoalkyl; R8 represents hydrogen; Ra is selected from C1-3alkyl and C1-3halogenoakryl. Other radicals are given in formula of invention.;EFFECT: compounds can be applied in manufacturing medication for prevention and/or treatment of predemential states, moderate cognitive failure and type II diabetes, Alzheimer's disease and Parkinson disease, as well as bone-associated malfunctions.;40 cl, 3 dwg, 1 tbl, 122 ex"/> NOVEL PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THERAPY, AS WELL AS APPLICATION OF PYRIMIDINE DERIVATIVES IN MANUFACTURING MEDICATION FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE
首页> 外国专利> NOVEL PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THERAPY, AS WELL AS APPLICATION OF PYRIMIDINE DERIVATIVES IN MANUFACTURING MEDICATION FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE

NOVEL PYRIMIDINE DERIVATIVES AND THEIR APPLICATION IN THERAPY, AS WELL AS APPLICATION OF PYRIMIDINE DERIVATIVES IN MANUFACTURING MEDICATION FOR PREVENTION AND/OR TREATMENT OF ALZHEIMER'S DISEASE

机译:新型嘧啶衍生物及其在治疗中的应用,以及嘧啶衍生物在制造预防和/或治疗老年痴呆症的药物中的应用

摘要

FIELD: medicine, pharmaceutics.;SUBSTANCE: claimed invention relates to novel pyrimidine derivatives or their pharmaceutically acceptable salts, possessing inhibiting activity with respect to glycogensintase kinase-3 (GSK3). In compound of formula I: R1 is selected from hydrogen, cyano, C1-3alogenoalkinyl, SO2NRbRc, C0-2alkyl(O)NRbRc, C1-4alkylNBbRc, SO2Ri, C(O)ORa, CH(OH)Rj and C(O)Rj; R2 and R4 are independently selected from hydrogen, halogeno, cyano, NO2, C1-4alkyl, C1-3ahalogenoalkyl, ORa, C(O)NRbRc, SO2Ri, and C(O)ORa; or R1 and R2 together with atoms, to which they are bound, are bound with formation of 5- or 6-member heterocyclic ring, which contains one S, any of the hydrogen atoms of group CH2 in said heterocyclic ring can be substituted by oxo, hydroxy, and sulphur atom in said heterocyclic ring is probably oxydised to -SO2-; R3 and R5 represent hydrogen; R6 represents tetrahydropyran; R7 is selected from hydrogen, C1-3alkyl, cyano and C1-3halogenoalkyl; R8 represents hydrogen; Ra is selected from C1-3alkyl and C1-3halogenoakryl. Other radicals are given in formula of invention.;EFFECT: compounds can be applied in manufacturing medication for prevention and/or treatment of predemential states, moderate cognitive failure and type II diabetes, Alzheimer's disease and Parkinson disease, as well as bone-associated malfunctions.;40 cl, 3 dwg, 1 tbl, 122 ex
机译:发明领域本发明涉及新颖的嘧啶衍生物或其药学上可接受的盐,其对糖原苷酶激酶-3(GSK3)具有抑制活性。在式I的化合物中: R 1 从氢中选择,氰基,C 1-3 芳族炔丙基,SO 2 NR b R c ,C 0- 2 烷基(O)NR b R c ,C 1-4 烷基NB b R < Sup> c ,SO 2 R i ,C(O)OR a ,CH(OH)R j 和C(O)R j ; R 2 和R 4 独立地选自氢,卤代,氰基,NO 2 ,C 1-4 烷基,C 1-3 卤代烷基,OR a ,C(O)NR b R c ,SO < Sub> 2 R i 和C(O)OR a ;或R 1 和R 2 与它们所键合的原子一起形成5或6员杂环,该环含有一个S,所述杂环中CH 2 基团的氢原子中的一个可以被氧,羟基取代,并且所述杂环中的硫原子可能被氧化为-SO 2 -; R 3 和R 5 代表氢; R 6 代表四氢吡喃; R 7 选自氢,C 1-3 烷基,氰基和C 1-3 卤代烷基; R 8 代表氢; R a 选自C 1-3 烷基和C 1-3 卤代卤代基。发明的通式中给出了其他基团;效果:这些化合物可以用于制造药物,用于预防和/或治疗痴呆,中度认知衰竭和II型糖尿病,阿尔茨海默氏病和帕金森氏病以及与骨相关的功能障碍。; 40 cl,3 dwg,1 tbl,122 ex

著录项

相似文献

  • 专利
  • 外文文献
  • 中文文献
获取专利

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号